TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18503493

Group type: EXPERIMENTAL
Intervention: Depressive symptoms
Number of subjects: 645

Group type: EXPERIMENTAL
Intervention: Perceived barriers to physical activity (e.g., poor health, fear, negative experiences, lack of knowledge)
Number of subjects: 645

Group type: EXPERIMENTAL
Intervention: Walking time over 10 m (adjustment)
Number of subjects: 645

Group type: EXPERIMENTAL
Intervention: Exercise promotion programs
Number of subjects: 645
Study: 17768009

Group type: EXPERIMENTAL
Intervention: Work style intervention (WS)
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: Combined intervention (WSPA)
Number of subjects: 466

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 466
Study: 14720530

Group type: EXPERIMENTAL
Intervention: Chronic low-frequency electrical stimulation (CLFS) of thigh muscles
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no muscle contractions, current input up to sensory threshold)
Number of subjects: 32
Study: 12103293

Group type: EXPERIMENTAL
Intervention: Cluster B flamboyant group (antisocial, histrionic)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Cluster A odd, eccentric group (schizoid, schizotypal, paranoid)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Cluster C anxious, fearful group (obsessional, avoidant)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Baseline and 12-year personality clusters
Number of subjects: 202
Study: 9689428

Group type: EXPERIMENTAL
Intervention: Ranitidine 4 x 150 mg or tetracycline 4 x 500 mg or metronidazole 3 x 250 mg for 2 weeks
Number of subjects: 201

Group type: COMPARATOR
Intervention: Placebo + tetracycline and metronidazole as in group A for 2 weeks
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Ranitidine combined with tetracycline and metronidazole
Number of subjects: 201

Group type: COMPARATOR
Intervention: Tetracycline and metronidazole alone
Number of subjects: 201
Study: 8206564

Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 202

Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 202

Group type: COMPARATOR
Intervention: Hydrochlorothiazide with oral potassium
Number of subjects: 202

Group type: COMPARATOR
Intervention: Hydrochlorothiazide with oral potassium and magnesium
Number of subjects: 202

Group type: COMPARATOR
Intervention: Hydrochlorothiazide and triamterene
Number of subjects: 202

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study: 2543309

Group type: EXPERIMENTAL
Intervention: Syo‐saiko‐to (7.5 g/day)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Conventional medicine (control group)
Number of subjects: 260
Study: 30738342

Group type: EXPERIMENTAL
Intervention: Expectation of teaching with unlimited motor preparation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Expectation of teaching with limited motor preparation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Expectation of being tested with unlimited motor preparation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Expectation of being tested with limited motor preparation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cumulative analysis from two prior experiments
Number of subjects: 0
Study: 28910291

Group type: EXPERIMENTAL
Intervention: Positive expectation induction with verbal suggestion (experimental group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Negative expectation induction (control group 1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Extinction procedure (control group 2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Histamine application test (after intervention)
Number of subjects: 0
Study: 26022817

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg, n = 519
Number of subjects: 1030

Group type: COMPARATOR
Intervention: Placebo, n = 511
Number of subjects: 1030
Study: 23651076

Group type: EXPERIMENTAL
Intervention: Oral sucrose (S)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Facilitated tucking (FT)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Combination of oral sucrose and facilitated tucking (SFT)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 25
Study: 22127194

Group type: EXPERIMENTAL
Intervention: nortriptyline
Number of subjects: 811

Group type: EXPERIMENTAL
Intervention: escitalopram
Number of subjects: 811
Study: 19162420

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 933

Group type: COMPARATOR
Intervention: Non-olanzapine antipsychotic
Number of subjects: 933

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 933
Study: 17682120

Group type: EXPERIMENTAL
Intervention: Cod protein diet
Number of subjects: 19

Group type: COMPARATOR
Intervention: BPVEM diet (lean beef, pork, veal, eggs, milk, and milk products)
Number of subjects: 19
Study: 15383197

Group type: EXPERIMENTAL
Intervention: 750 mg levofloxacin
Number of subjects: 528

Group type: COMPARATOR
Intervention: 500 mg levofloxacin
Number of subjects: 528
Study: 15231903

Group type: EXPERIMENTAL
Intervention: Chelation therapy with succimer
Number of subjects: 780

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 780
Study: 10931120

Group type: EXPERIMENTAL
Intervention: Atopic rhinitic children
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Atopic control children
Number of subjects: 375

Group type: COMPARATOR
Intervention: Nonatopic rhinitic subjects
Number of subjects: 375

Group type: COMPARATOR
Intervention: Nonatopic control subjects
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Children with positive skin response to CRM
Number of subjects: 375

Group type: COMPARATOR
Intervention: Children without sensitization to CRM
Number of subjects: 375
Study: 9485981

Group type: EXPERIMENTAL
Intervention: atracurium
Number of subjects: 50

Group type: COMPARATOR
Intervention: vecuronium
Number of subjects: 50
Study: 8150546

Group type: EXPERIMENTAL
Intervention: Amlodipine (2.5 to 10 mg) once daily
Number of subjects: 139

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ) (25 to 100 mg) daily
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Amlodipine-atenolol combination therapy
Number of subjects: 139

Group type: COMPARATOR
Intervention: HCTZ-atenolol combination therapy
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 139

Group type: COMPARATOR
Intervention: HCTZ
Number of subjects: 139
Study: 3538937

Group type: EXPERIMENTAL
Intervention: Ketamine and flunitrazepam with N2O/O2 ventilation
Number of subjects: 21

Group type: COMPARATOR
Intervention: Neuroleptic analgesia (NLA)
Number of subjects: 21
Study: 28857388

Group type: EXPERIMENTAL
Intervention: Metformin extended-release (XR) 2000 mg once daily
Number of subjects: 539

Group type: COMPARATOR
Intervention: Metformin immediate-release (IR) 1000 mg twice daily
Number of subjects: 539
Study: 27413042

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg/day
Number of subjects: 12527

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12527
Study: 24432923

Group type: EXPERIMENTAL
Intervention: HIV/sexually transmitted infection (STI) risk-reduction intervention targeting condom use
Number of subjects: 1181

Group type: COMPARATOR
Intervention: Attention-matched control targeting health issues unrelated to sexual risks
Number of subjects: 1181
Study: 22081257

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 20023577

Group type: EXPERIMENTAL
Intervention: Carmellose 0.5%
Number of subjects: 15

Group type: COMPARATOR
Intervention: Hyaluronate 0.15%
Number of subjects: 15
Study: 17675317

Group type: EXPERIMENTAL
Intervention: NIV
Number of subjects: 8

Group type: COMPARATOR
Intervention: Air (placebo)
Number of subjects: 8
Study: 16819355

Group type: EXPERIMENTAL
Intervention: Digital subtraction angiography (DSA)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: B-mode ultrasonography
Number of subjects: 19
Study: 12814444

Group type: EXPERIMENTAL
Intervention: Moxonidine sustained release (1.5 mg o.d.)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 10574168

Group type: EXPERIMENTAL
Intervention: Physical Therapy (PT)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Occupational Therapy (OT)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control Therapy (CT)
Number of subjects: 135
Study: 8908663

Group type: EXPERIMENTAL
Intervention: Vaginal electrical stimulation using Conmax and Medicon MS‐105 at frequencies of 10, 20, and 50 Hz
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Vaginal electrical stimulation using Conmax and Medicon MS‐105
Number of subjects: 9
Study: 2058867

Group type: EXPERIMENTAL
Intervention: Low potassium intake (16 mmol/day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: High potassium intake (96 mmol/day)
Number of subjects: 12
Study: 6342837

Group type: EXPERIMENTAL
Intervention: Metoprolol (15 mg i.v. + 200 mg/day) for 90 days
Number of subjects: 1395

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1395

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 1395
Study: 31124367

Group type: EXPERIMENTAL
Intervention: Liberal perioperative oxygen therapy (≥80% oxygen)
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Routine titration of inspired oxygen
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Minimising oxygen administration
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Maximising oxygen administration
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Targeted intraoperative fraction inspired oxygen (FiO2)
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Willingness to participate in future studies
Number of subjects: 282
Study: 28137475

Group type: EXPERIMENTAL
Intervention: Yearlong multicomponent rehabilitation program
Number of subjects: 81

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 81
Study: 25596881

Group type: EXPERIMENTAL
Intervention: Levodopa treatment initiated after baseline assessment
Number of subjects: 403

Group type: COMPARATOR
Intervention: Baseline cerebrospinal fluid (CSF) biomarkers
Number of subjects: 403
Study: 23980876

Group type: EXPERIMENTAL
Intervention: Intratumoral plasmid AMEP electrotransfer (1 and 2 mg DNA)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control lesions (untreated)
Number of subjects: 5
Study: 21378141

Group type: EXPERIMENTAL
Intervention: Rhythmic lower-leg cuff inflation (RCI) at 80 mmHg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Rhythmic lower-leg cuff inflation (RCI) at 120 mmHg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Rhythmic lower-leg cuff inflation (RCI) at 40 mmHg
Number of subjects: 11

Group type: COMPARATOR
Intervention: Sham condition (0 mmHg)
Number of subjects: 11
Study: 19411053

Group type: EXPERIMENTAL
Intervention: Intervention group (n = 50) watched 4 weekly episodes of the cooking show, Good Grubbin'
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group (n = 51) watched 4 weekly episodes on sleep disorders
Number of subjects: 101
Study: 17724537

Group type: EXPERIMENTAL
Intervention: Therapeutic guidelines for the treatment of nosocomial pneumonia (group with intervention)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Historical controls (group without intervention)
Number of subjects: 0
Study: 15277150

Group type: EXPERIMENTAL
Intervention: Vigorous-intensity exercise program (30 min 3 times/wk)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Energy restriction (4186-6279 kJ/d)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Vigorous-intensity exercise program
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Energy restriction
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Vigorous-intensity exercise and energy restriction
Number of subjects: 60
Study: 12040756

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen treatment (HBO)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Delayed treatment group (no HBO)
Number of subjects: 7
Study: 9808859

Group type: EXPERIMENTAL
Intervention: Sublingual glyceryl trinitrate (GTN) 800 microg
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Sublingual glyceryl trinitrate (GTN)
Number of subjects: 47
Study: 7622990

Group type: EXPERIMENTAL
Intervention: Motor practice (immediate imitation) before the delay
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: No motor practice before the delay
Number of subjects: 192

Group type: COMPARATOR
Intervention: Age-matched control groups
Number of subjects: 192
Study: 2539204

Group type: EXPERIMENTAL
Intervention: Imipramine (2.5 mg/kg/day)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Tyrosine (100 mg/kg/day)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 190594

Group type: EXPERIMENTAL
Intervention: Structured preoperative educational program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standardized questionnaires
Number of subjects: 0
Study: 6185089

Group type: EXPERIMENTAL
Intervention: Topical arabinosyladenine monophosphate (ara-AMP)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 31705750

Group type: EXPERIMENTAL
Intervention: Chronic Kidney Disease (CKD)
Number of subjects: 9361

Group type: COMPARATOR
Intervention: No Chronic Kidney Disease (Control)
Number of subjects: 9361

Group type: EXPERIMENTAL
Intervention: Chronic Kidney Disease (CKD) with intensive blood pressure reduction
Number of subjects: 9361

Group type: EXPERIMENTAL
Intervention: Clinical cardiovascular disease
Number of subjects: 9361
Study: 25559249

Group type: EXPERIMENTAL
Intervention: Core strength training on unstable surfaces (CSTU)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Core strength training on stable surfaces (CSTS)
Number of subjects: 39
Study: 24869931

Group type: EXPERIMENTAL
Intervention: Pertuzumab, Trastuzumab, and Docetaxel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (Placebo)
Number of subjects: 0
Study: 22733899

Group type: EXPERIMENTAL
Intervention: 80-kVp protocol with moderate-concentration CM
Number of subjects: 50

Group type: COMPARATOR
Intervention: 120-kVp protocol with high-concentration CM
Number of subjects: 50
Study: 21203735

Group type: EXPERIMENTAL
Intervention: 10 percent sodium ascorbate gel combined with a surfactant
Number of subjects: 40

Group type: COMPARATOR
Intervention: 10 percent carbamide peroxide without an antioxidant agent
Number of subjects: 40
Study: 17641514

Group type: EXPERIMENTAL
Intervention: Partial breast irradiation (PBI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Whole-breast irradiation
Number of subjects: 0
Study: 15329918

Group type: EXPERIMENTAL
Intervention: Doxorubicin (DOX)
Number of subjects: 130

Group type: COMPARATOR
Intervention: No Doxorubicin (no DOX)
Number of subjects: 130
Study: 11060829

Group type: EXPERIMENTAL
Intervention: Lotrafiban
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin therapy
Number of subjects: 0
Study: 9013308

Group type: EXPERIMENTAL
Intervention: Full bladder (group F)
Number of subjects: 796

Group type: COMPARATOR
Intervention: Empty bladder (group E)
Number of subjects: 796
Study: 8357055

Group type: EXPERIMENTAL
Intervention: betaxolol 0.5%
Number of subjects: 76

Group type: COMPARATOR
Intervention: dipivefrin 0.1%
Number of subjects: 76
Study: 3510821

Group type: EXPERIMENTAL
Intervention: Eating a high-carbohydrate meal
Number of subjects: 184

Group type: COMPARATOR
Intervention: Fasting
Number of subjects: 184
Study: 28240687

Group type: EXPERIMENTAL
Intervention: Liberal transfusion strategy (hemoglobin threshold < 9 g/dL)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Restrictive transfusion strategy (hemoglobin threshold < 7 g/dL)
Number of subjects: 300
Study: 26458258

Group type: EXPERIMENTAL
Intervention: Red wine
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Both wine groups
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Both wines
Number of subjects: 224

Group type: COMPARATOR
Intervention: Mineral water (control)
Number of subjects: 224
Study: 23880333

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) group, 8 weeks duration, 1 session per week, 100 minutes per session
Number of subjects: 60

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) group
Number of subjects: 60
Study: 23724267

Group type: EXPERIMENTAL
Intervention: Maxillary sinus antrostomy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Uncinectomy-only
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both procedures
Number of subjects: 30
Study: 18853428

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg once daily
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 17499084

Group type: EXPERIMENTAL
Intervention: Self-administered ERP
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Therapist-administered ERP
Number of subjects: 41
Study: 15240647

Group type: EXPERIMENTAL
Intervention: Isoflavonoids (114 mg/d)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 11802014

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg twice a day for 2 months
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo for 2 months
Number of subjects: 53
Study: 9587133

Group type: EXPERIMENTAL
Intervention: Plasmacytic hyperplasia (PH)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Polymorphic PT‐LPD
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Malignant lymphoma/multiple myeloma (ML/MM)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Reduction in immunosuppression
Number of subjects: 32
Study: 7870393

Group type: EXPERIMENTAL
Intervention: New algorithm for volume determination by SPECT (moment‐preserving bilevel thresholding and best‐fit Laplacian second derivative edge detection)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New algorithm for volume determination by SPECT
Number of subjects: 0
Study: 3130925

Group type: EXPERIMENTAL
Intervention: Single dose of 60 mg APD intravenously
Number of subjects: 30

Group type: COMPARATOR
Intervention: Daily doses of 30 mg APD (two days) or 15 mg (four days)
Number of subjects: 30
Study: 31290697

Group type: EXPERIMENTAL
Intervention: Juice-based targeted medical nutrition (TMN) supplement (∼200 kcal; 10 g whey protein; ≥2.0 g eicosapentaenoic acid/docosahexaenoic acid in fish oil; and 10 μg 25-hydroxy-vitamin D3)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Milk-based isocaloric comparator
Number of subjects: 55
Study: 31892700

Group type: EXPERIMENTAL
Intervention: Weedy Amaranthus genotypes (A. viridis WAV7 and A. spinosus WAS13)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Weedy Amaranthus genotypes
Number of subjects: 6
Study: 28433366

Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive (150 μg levonorgestrel and 30 μg ethinylestradiol)
Number of subjects: 340

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 340
Study: 26452543

Group type: EXPERIMENTAL
Intervention: CARE4STROKE program (8 weeks) in addition to usual care
Number of subjects: 66

Group type: COMPARATOR
Intervention: Usual care alone (8 weeks)
Number of subjects: 66
Study: 22852760

Group type: EXPERIMENTAL
Intervention: Valacyclovir
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21865022

Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 19181969

Group type: EXPERIMENTAL
Intervention: Initial surgical stabilization (18 patients)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nonoperative treatment with orthosis (22 patients)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 17917772

Group type: EXPERIMENTAL
Intervention: Fibrin glue used as reinforcement on primary end-to-end esophageal anastomosis (Group A)
Number of subjects: 52

Group type: COMPARATOR
Intervention: No fibrin glue used (Group B)
Number of subjects: 52
Study: 15535794

Group type: EXPERIMENTAL
Intervention: Psychopathic Personality Inventory (self-report instrument)
Number of subjects: 309
Study: 11804384

Group type: EXPERIMENTAL
Intervention: Various treatment approaches (surgery, radiation, chemotherapy, BSC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Future prospective randomized studies
Number of subjects: 0
Study: 9440748

Group type: EXPERIMENTAL
Intervention: Single-dose (pulse-intensive [PI]) treatment with dactinomycin for low-risk patients
Number of subjects: 1687

Group type: COMPARATOR
Intervention: Divided-dose (standard [STD]) treatment with dactinomycin for low-risk patients
Number of subjects: 1687

Group type: EXPERIMENTAL
Intervention: Single-dose (pulse-intensive [PI]) treatment with doxorubicin for high-risk patients
Number of subjects: 1687

Group type: COMPARATOR
Intervention: Divided-dose (standard [STD]) treatment with doxorubicin for high-risk patients
Number of subjects: 1687
Study: 7919071

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extracranial-intracranial bypass surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ongoing trials in patients with asymptomatic bruits and other problems
Number of subjects: 0
Study: 2684073

Group type: EXPERIMENTAL
Intervention: Betaxolol (20 mg once daily)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Chlorthalidone (25 mg once daily)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Combination of Betaxolol and Chlorthalidone
Number of subjects: 186
Study: 31000379

Group type: EXPERIMENTAL
Intervention: Lidocaine and phenylephrine nasal spray (10 mg lidocaine and 1 mg phenylephrine for children weighing 6–12 kg; 20 mg lidocaine and 2 mg phenylephrine for children weighing >12 kg)
Number of subjects: 107

Group type: COMPARATOR
Intervention: 0.9% sodium chloride placebo nasal spray
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Lidocaine and phenylephrine nasal spray
Number of subjects: 107
Study: 28463902

Group type: EXPERIMENTAL
Intervention: High-volume training (HYPER)
Number of subjects: 38

Group type: COMPARATOR
Intervention: One repetition maximum (1RM) strength test (TEST)
Number of subjects: 38
Study: 25540891

Group type: EXPERIMENTAL
Intervention: EBO vaccine
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: MAR vaccine
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 108
Study: 23887226

Group type: EXPERIMENTAL
Intervention: High-load strength training (16 weeks, 3 times a week)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control period (16 weeks)
Number of subjects: 23